Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 613-617

  Huang, Ta Chen ^a,b   Campbell, Toby C ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Neutropenia; Paclitaxel; Sensory neuropathy; Solid cancer; Weekly

Indexed keywords

CARBOPLATIN; CETUXIMAB; PACLITAXEL; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INFUSION; ETHNICITY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SOLID TUMOR; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84861693322     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.10.008     Document Type: Review

References (28)

1. Giaccone G., Splinter T.A., Debruyne C., et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998, 16(6):2133-2141.
2. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334(1):1-6.
3. Holmes F.A., Walters R.S., Theriault R.L., et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83(24):1797-1805.
4. Yeh K.H., Lu Y.S., Hsu C.H., et al. Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer. Oncology 2005, 69(1):88-95.
5. Lin C.C., Yeh K.H., Yang C.H., et al. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. Anticancer Drugs 2007, 18(6):703-708.
6. Ball H.G., Blessing J.A., Lentz S.S., Mutch D.G. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996, 62(2):278-281.
7. Papadimitriou C.A., Sarris K., Moulopoulos L.A., et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol 1999, 17(3):761-766.
8. Lin C.C., Hsu C.H., Hour T.C., et al. Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial. Urol Oncol 2007, 25(3):207-213.
9. Pivot X., Cals L., Cupissol D., et al. Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck. Oncology 2001, 60(1):66-71.
10. Steinert D.M., Patel S.R. Recent studies in novel therapy for metastatic sarcomas. Hematol Oncol Clin North Am 2005, 19(3):573-590. viii.
11. Colburn D.E., Thomas D.A., Giles F.J. Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia. Invest New Drugs 2003, 21(1):109-111.
12. Rizzieri D.A., Sand G.J., McGaughey D., et al. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer 2004, 100(11):2408-2414.
13. Rosenberg P., Andersson H., Boman K., et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002, 41(5):418-424.
14. Sakakibara T., Inoue A., Sugawara S., et al. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2010, 21(4):795-799.
15. Perez E.A., Suman V.J., Rowland K.M., et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005, 6(5):425-432.
16. Socinski M.A., Ivanova A., Bakri K., et al. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 2006, 17(1):104-109.
17. Socinski M.A., Saleh M.N., Trent D.F., et al. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol 2009, 20(6):1068-1073.
18. Shen K., Li M.D., Feng Y.J., et al. A multicenter randomized clinical trial of weekly paclitaxel and carboplatin vs three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer. Zhonghua Yi Xue Za Zhi 2005, 85(30):2099-2103.
19. Belani C.P., Ramalingam S., Perry M.C., et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(3):468-473.
20. Seidman A.D., Berry D., Cirrincione C., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008, 26(10):1642-1649.
21. Katsumata N., Yasuda M., Takahashi F., et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374(9698):1331-1338.
22. Nabholtz J.M., Gelmon K., Bontenbal M., et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996, 14(6):1858-1867.
23. Peltier A.C., Russell J.W. Advances in understanding drug-induced neuropathies. Drug Saf 2006, 29(1):23-30.
24. Winer E.P., Berry D.A., Woolf S., et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004, 22(11):2061-2068.
25. Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006, 24(10):1633-1642.
26. Sparreboom A., van Tellingen O., Nooijen W.J., Beijnen J.H. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996, 56(9):2112-2115.
27. Schuette W., Blankenburg T., Guschall W., et al. Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer 2006, 7(5):338-343.
28. Mauri D., Kamposioras K., Tsali L., et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev 2010, 36(1):69-74.